Reeses Tabtussin
NDC Package 10956-161-24

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Reeses Tabtussin is • Adults and children 12 years of age and over: take 1 tablet every 4 hours as needed     • Children 610 under 12 years of age: take 1/2 tablet every 4 hours as needed • Children under 6 years of age: consult a doctor Do not exceed 6 doses in a 24 hour period or as directed by a doctor Other information store at 15'- 30' C (59'- 86'F)     Rev 10/U9 RCCF. Marketed by Reese Pharmaceutical Co, this product is identified by NDC 10956-161 and is authorized under FDA application part341.

Identification & Billing

NDC Package Code
10956-161-24
Package Description
2 BLISTER PACK in 1 CARTON / 12 TABLET in 1 BLISTER PACK
Product Code
10956-161
11-Digit Billing Format
10956016124
RxNorm Crosswalk
  • RxCUI: 1147685 - dextromethorphan HBr 20 MG / guaiFENesin 400 MG Oral Tablet
  • RxCUI: 1147685 - dextromethorphan hydrobromide 20 MG / guaifenesin 400 MG Oral Tablet
  • RxCUI: 1147685 - guaifenesin 400 MG / dextromethorphan HBr 20 MG Oral Tablet

Clinical Specifications

Proprietary Name
Reeses Tabtussin DM
Dosage Form
-
Usage Information
• Adults and children 12 years of age and over: take 1 tablet every 4 hours as needed     • Children 610 under 12 years of age: take 1/2 tablet every 4 hours as needed • Children under 6 years of age: consult a doctor Do not exceed 6 doses in a 24 hour period or as directed by a doctor Other information store at 15'- 30' C (59'- 86'F)     Rev 10/U9 RCCF

Regulatory & Marketing

Labeler Name
Reese Pharmaceutical Co
FDA Application #
part341
Marketing Category
OTC MONOGRAPH FINAL - A product marketed pursuant to a final Over-the-Counter (OTC) Drug Monograph.
Start Marketing Date
03-11-2021
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 10956-161-24 identifies a specific commercial package of 2 blister pack in 1 carton / 12 tablet in 1 blister pack of Reeses Tabtussin DM, labeled by Reese Pharmaceutical Co. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Reese Pharmaceutical Co on March 11, 2021. The current certification is valid through December 31, 2022.

How is this Reese Pharmaceutical Co product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 10956016124. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
10956-161-24
11-Digit CMS (5-4-2)
10956-0161-24

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.